Review: Barrett's esophagus and the increasing role of endoluminal therapy

Therapeutic Advances in Gastroenterology

Volumn 1, Issue 2, 2008, Pages 121-142

  Smith, Michael S ^a   Lightdale, Charles J ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

Barrett's esophagus; esophageal cancer; gastro esophageal reflux disease

Indexed keywords

EID: 84993728263     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X08095883     Document Type: Review

References (148)

1. Abe, Y., Ohara, S., Koike, T., Sekine, H., Iijima, K., Kawamura, M. et al. (2004) The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol 99: 1213-1221.
2. Abrams, J.A., Fedi, P., Vakiani, E., Hatefi, D., Remotti, H.E. and Lightdale, C.J. (2008) Depth of resection using two different endoscopic mucosal resection techniques. Endoscopy 40: 395-399.
3. Ackroyd, R., Brown, N.J., Davis, M.F., Stephenson, T.J., Marcus, S.L., Stoddard, C.J. et al. (2000) Photodynamic therapy for dysplastic Barrett's esophagus: a prospective, double blind, randomised, placebo-controlled trial. Gut 47: 613-617.
4. Ackroyd, R., Brown, N.J., Stephenson, T.J., Stoddard, C.J. and Reed, M.W. (1999) Ablation treatment for Barrett esophagus: what depth of tissue destruction is needed. J Clin Pathol 52: 509-512.
5. Anderson, L.A., Murray, L.J., Murphy, S.J., Fitzpatrick, D.A., Johnston, B.T., Watson, R.G.P. et al. (2003) Mortality in Barrett's esophagus: results from a population based study. Gut 52: 1081-1084.
6. Attwood, S.E.A. and Morris, C.D. (2001) Who defines Barrett's esophagus: endoscopist or pathologist. Eur J Gastroenterol 13: 97-99.
7. Banki, F., de Meester, S.R., Mason, R.J., Campus, G., Hagen, J.A., Peters, J.H. et al. (2005) Barrett's esophagus in females: a comparative analysis of risk factors in females and males. Am J Gastroenterol 100: 560-567.
8. Barham, C.P., Shepherd, N. and Barr, H. (1996) Regression of Barrett's epithelium using argon gas coagulation and acid suppression. Gut 39: 114.
9. Barr, H. (2000) Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. Gastrointest Clin Endoscop N Am 10: 421-438.
10. Barr, H., Stone, N. and Rembacken, B. (2005) Endoscopic therapy for Barrett's esophagus. Gut 54: 875-884.
11. Barrett, N.R. (1950) Chronic peptic ulcer of the esophagus and ‘esophagitis’. Br J Surg 38: 175-182.
12. Barrett, N.R. (1957) The lower esophagus lined by columnar epithelium. Surgery 41: 881-894.
13. Bergman, J.J. (2005) Diagnosis and therapy of early neoplasia in Barrett's esophagus. Curr Opin Gastroenterol 21: 466-471.
14. Biddlestone, L.R., Barham, C.P., Wilkinson, S.P., Barr, H. and Shepherd, N.A. (1998) The histopathology of treated Barrett's esophagus. Am J Surg Pathol 22: 239-245.
15. Birkmeyer, J.D., Siewers, A.E., Finlayson, E.V., Stukel, T.A., Lucas, F.L., Batista, I. et al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346: 1128-1137.
16. Blot, W.J., Devesa, S.S., Kneller, R.W. and Fraumeni Jr, J.F. (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289.
17. Bollschweiler, E., Wolfgarten, E., Gutschow, C. and Holscher, A.H. (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92: 549-555.
18. Bonino, J.A. and Sharma, P. (2005) Barrett's esophagus. Curr Opin Gastroenterol 21: 461-465.
19. Bonino, J.A. and Sharma, P. (2006) Barrett's esophagus. Curr Opin Gastroenterol 22: 406-411.
20. Buskens, C.J., van Rees, B.P., Sivula, A., Reitsma, J.B., Haglund, C., Bosma, P.J. et al. (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122: 1800-1807.
21. Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A. et al. (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122: 1101-1112.
22. Buttar, N.S., Wang, K.K., Lutzke, L. and Krishnadath, K. (2001 a) The use of endoscopic ultrasound in Barrett's esophagus. Gastrointest Endosc 53: AB172.
23. Buttar, N.S., Wang, K.K., Lutzke, L.S., Krishnadath, K.K. and Anderson, M.A. (2001 b) Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 54: 682-688.
24. Buttar, N.S., Wang, K.K., Sebo, T.J., Riehle, D., Krishnadath, K., Lutzke, L. et al. (2001 c) Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120: 1630-1639.
25. Cameron, A.J. (1997) Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin N Am 26: 487-494.
26. Cameron, A.J., Ott, B.J. and Payne, W.S. (1985) The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313: 857-858.
27. Cameron, A.J., Zinsmeister, A.R., Ballard, D.J. and Carney, J.A. (1990) Prevalence of columnar-lined Barrett's esophagus: comparison of population based on clinical and autopsy findings. Gastroenterology 99: 918-922.
28. Castell, D.O. (2001) Medical, surgical, and endoscopic treatment of gastresophageal reflux disease and Barrett's esophagus. J Clin Gastroenterol 33: 262-266.
29. Chak, A., Faulx, A., Kinnard, M., Brock, W., Willis, J., Wiesner, G.L. et al. (2004) Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 99: 2107-2114.
30. Coad, R.A., Woodman, A.C., Warner, P.J., Barr, H., Wright, N.A. and Shepherd, N.A. (2005) On the histogenesis of Barrett's esophagus and its associated squamous islands: a three-dimensional study of their morphological relationship with native esophageal gland ducts. J Pathol 206 (4): 388-94.
31. Conio, M., Blanchi, S., Lapertosa, G., Ferraris, R., Sablich, R., Marchi, S. et al. (2003) Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 98: 1931-1939.
32. Connor, M., Weston, A.P., Mayo, M.S. and Sharma, P. (2004) The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population. Dig Dis Sci 49: 920-924.
33. Corley, D.A., Levin, T.R., Habel, L.A., Weiss, N. and Buffler, P. (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122: 633-640.
34. Csendes, A., Braghetto, I., Burdiles, P., Puente, G., Korn, O., Diaz, J.C. et al. (1998) Long-term results of classic anti-reflux surgery in 152 patients with Barrett's esophagus. Surgery 123: 645-657.
35. Das, A., Wells, C.D., Fleischer, D.E., Kim, H.J. and Sharma, V.K. (2007) Endoscopic ablative therapy is a cost-effective management for non-dysplastic Barrett esophagus. Gastrointest Endosc 65: AB151.
36. de Meester, S.R. and de Meester, T.R. (2000) Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg 231: 303-321.
37. Devesa, S.S., Blot, W.J. and Fraumeni Jr, J.F. (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053.
38. Dulai, G., Jensen, D.M. and Cortina, G. (2004) MPEC is superior to APC in sustained ablation of Barrett's. Gastroenterology 126: A35.
39. Ell, C., May, A., Gossner, L., Pech, O., Gunter, E., Mayer, G. et al. (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118: 670-677.
40. El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A. and Sampliner, R.E. (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99: 1877-1883.
41. El-Serag, H.B., Kvapil, P., Hacken-Bitar, J. and Kramer, J.R. (2005) Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 100: 2151-2156.
42. Falk, G.W. (2002) Barrett's esophagus. Gastroenterology 122: 1569-1591.
43. Farrow, D.C. and Vaughan, T.L. (1996) Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 7: 322-327.
44. Farrow, D.C., Vaughan, T.L., Hansten, P.D., Stanford, J.L., Risch, H.A., Gammon, M.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol Biomarkers Prev 3: 97-102.
45. Fitzgerald, R.C., Omary, M.B. and Triadofilopoulos, G. (1996) Dynamic effects of acid on Barrett's esophagus. J Clin Invest 98: 2120-2128.
46. Fleischer, D., Overholt, B., Sharma, V.K., Reymunde, A., Kimmey, M., Chuttani, R. et al. (2007) Follow-up of AIM-II trial for ablation of Barrett esophagus: results after primary circumferential ablation followed by secondary focal ablation. Gastrointest Endosc 65: AB135.
47. Franchimont, D., van Laethem, J.-L. and Deviere, J. (2003) Argon plasma coagulation in Barrett's esophagus. Gastrointest Clin Endoscop N Am 13: 457-466.
48. Funkhouser, E.M. and Sharp, G.B. (1995) Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116-1119.
49. Ganz, R., Overholt, B., Sharma, V.K., Panjehpour, M., de Meester, S.R., Bohorfoush, A. et al. (2007) Halo 360 circumferential ablation is safe and effective for the treatemtn of Barrett esophagus and high-grade dysplasia: a US multi-center registry. Gastrointest Endosc 65: AB147.
50. Gillen, P., Keeling, P., Byrne, P.J., Healy, M., O'Moore, R.R. and Hennessy, T.P. (1988) Implication of duodenogastric reflux in the pathogenesis of Barrett's esophagus. Br J Surg 75: 540-543.
51. Giovannini, M., Bories, E., Pesenti, C., Moutardier, V., Mongest, G., Danisi, C. et al. (2004) Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 36: 782-787.
52. Gondrie, J.J., Peters, F.P., Curvers, W.L., Sondermeijer, C.M., ten Kate, F., Fockens, P. et al. (2007 a) Radiofrequency ablation of Barrett's esophagus containing high-grade dysplasia. Gastrointest Endosc 65: AB135.
53. Gondrie, J.J., Rygiel, A.M., Sondermeijer, C.M., Fockens, P., ten Kate, F., Krishnadath, K.K. et al. (2007 b) Balloon-based circumferential ablation followed by focal ablation of Barrett esophagus containing high-grade dysplasia effectively removes all genetic alterations. Gastrointest Endosc 132: AB64.
54. Gossner, L., May, A., Stolte, M., Seitz, G., Hahn, E.G. and Ell, C. (1998 a) KTP-laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 49: 8-12.
55. Gossner, L., Stolte, M., Sroka, R., Rick, K., May, A., Hahn, E. et al. (1998 b) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 114: 448-455.
56. Haggitt, R.C. (1994) Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25: 982-993.
57. Headrick, J.R., Nichols, F.C.III, Miller, D.L., Allen, M.S., Trastek, V.F., Deschamps, C. et al. (2002) High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 73: 1697-1702.
58. Heier, S.K., Rothman, K.A., Heier, L.M. and Rosenthal, W.S. (1995) Photodynamic therapy for obstructing esophageal cancer: light dosimetry and a randomized comparison with Nd : YAG laser therapy. Gastroenterology 109: 63-72.
59. Hesketh, P.J., Clapp, R.W., Doos, W.G. and Spechler, S.J. (1989) The increasing frequency of adenocarcinoma of the esophagus. Cancer 64: 526-530.
60. Hetzel, D.J., Dent, J., Reed, W.D., Nerielvala, F.M., Mackinnon, M., McCarthy, J.H. et al. (1988) Healing and relapse of severe peptic esophagitis after treatement with omeprazole. Gastroenterology 95: 903-12.
61. Holscher, A.H., Bollschweiler, E., Schneider, P.M. and Siewert, J.R. (1997) Early adenocarcinoma in Barrett's esophagus. Br J Surg 84: 1470-1473.
62. Inadomi, J.M., Madanick, R.D., Somsouk, M. and Shaheen, N.J. (2007) Radiofrequency ablation is more cost-effective than endoscopic surveillance or esophagectomy among patients with Barrett's esophagus and low-grade dysplasia. Gastrointest Endosc 132: AB53.
63. Inadomi, J.M., Sampliner, R., Lagergren, J., Lieberman, D., Fendrick, A.M. and Vakil, N. (2003) Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utility analysis. Ann Int Med 138: 176-186.
64. Irani, S., Parkman, H.P., Thomas, R., Krevsky, B., Fisher, R.S. and Axelrod, P. (2005) Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center. Dig Dis Sci 50: 2141-2146.
65. Johnston, M.H., Eastone, J.A., Horwhat, J.D., Cartledge, J., Mathews, J.S. and Foggy, J.R. (2005) Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc 62: 842-848.
66. Kapoor, N., Ragunath, K., Raman, V.S.V.S., Haqqani, M.T.M.T. and Krasner, N. (2002) Endoscopic ablation of dysplastic Barrett's esophagus comparing argon plasma coagulation and photodynamic therapy: long term results of a randomised prospective trial. Gut 34(Suppl II): A27.
67. Katzka, D. and Castell, D.O. (1994) Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus. Am J Gastroentrol 89: 989-991.
68. Kim, R., Weissfeld, J.L., Reynolds, J.C. and Kuller, L.H. (1997) Etiology of Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 6: 369-377.
69. Kodama, M. and Kakegawa, T. (1998) Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 123: 432-439.
70. Lagergren, J. (2005) Adenocarcinoma of esophagus: what exactly is the size of the problem and who is at risk? Gut 54 Suppl 1: 1-5.
71. Lagergren, J., Bergstrom, R., Lindgren, A. and Nyren, O. (1999) Symptomatic gastro-esophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825-831.
72. Larghi, A., Lightdale, C.J., Memeo, L., Bhagat, G., Okpara, N. and Rotterdam, H. (2005) EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 62: 16-23.
73. Levine, D.S. and Reid, B.J. (1991) Endoscopic technique for acquiring larger mucosal samples. Gastrointest Endosc 37: 332-337.
74. Lightdale, C.J. (1999) Ablation therapy for Barrett's esophagus: is it time to choose our weapons? Gastrointest Endosc 49: 122-125.
75. Lightdale, C.J., Larghi, A., Rotterdam, H. and Okpara, N. (2004) Endoscopic ultrasonography (EUS) and endoscopic mucosal resection (EMR) for staging and treatment of high-grade dysplasia (HGD) and early adenocarcinoma (EAC) in Barrett's esophagus (BE). Gastrointest Endosc 59: 90.
76. Lin, M., Gerson, L.B., Lascar, R., Davila, M. and Triadafilopoulos, G. (2004) Features of gastresophageal reflux disease in women. Am J Gastroenterol 99: 1442-1447.
77. Locke, G.R., Talley, N.J., Fett, S.L., Zinsmeister, A.R. and Melton, 3rd L.J. (1997) Prevalence and clinical spectrum of gastresophageal reflux disease: a population based study in Olmsted County, Minnesota. Gastroenterology 112: 1448-1456.
78. Maieron, R., Elli, L., Marino, M., Floriani, I., Minerva, F., Avellini, C. et al. (2005) Celiac disease and intestinal metaplasia of the esophagus (Barrett's esophagus). Dig Dis Sci 50: 126-129.
79. Martin, W.R., Benz, C., Jakobs, R. and Riemann, J.F. (1998) Argon plasma coagulation (APC) in patients with Barrett's esophagus, Gastroenterology 114: A60.
80. Mashimo, H., Wagh, M.S. and Goyal, R.K. (2005) Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol 39(Suppl. 2): S33-S41.
81. May, A., Gossner, L., Pech, O., Fritz, A., Gunter, E., Mayer, G. et al. (2002) Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's esophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 14: 1085-1091.
82. Montgomery, E., Bronner, M.P., Goldblum, J.R., Greenson, J.K., Haber, M.M., Hart, J. et al. (2001) Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol 32: 368-378.
83. Montgomery, E., Goldblum, J.R., Greenson, J.K., Haber, M.M., Lamps, L.W., Lauwers, G.Y. et al. (2001) Dysplasia as a predictive marker for invasive cancer in Barrett's esophagus: a follow up study based on 138 cases from a diagnostic variability study. Hum Pathol 32: 379-388.
84. Nebel, O.T., Fornes, M.F. and Castell, D.O. (1976) Symptomatic gastresophageal reflux: incidence and precipitating factors. Am J Dig Dis 21: 953-956.
85. O'Sullivan, G.C., Sheehan, D., Clarke, A., Stuart, R., Kelly, J., Kiely, M.D. et al. (1999) Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 116: 543-548.
86. Ouatu-Lascar, R., Fitzgerald, R.C. and Triadafilopoulos, G. (1999) Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117: 327-335.
87. Overholt, B.F., Panjehpour, M. and Halberg, D.L. (2003) Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 54: 183-188.
88. Overholt, B.F., Wang, K.K., Burdick, J.S., Lightdale, C.J., Kimmey, M., Nava, H.R. et al. (2007) International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 66: 460-468.
89. Pasricha, P.J., Hill, S., Wadwa, K.S., Gislason, G.T., Okolo, P.I.III, Magee, C.A. et al. (1998) A second generation endoscopic cryospray: experimental results and first clinical use. Gastrointest Endosc 47: 76.
90. Pech, O., Gossner, L., May, A., Rabenstein, T., Vieth, M., Stolte, M. et al. (2005) Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 62: 24-30.
91. Peghini, P.L., Katz, P.O., Bracy, N.A. and Castell, D.O. (1989) Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 93: 763-767.
92. Pera, M. (2000) Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Cancer Res 155: 1-14.
93. Peters, F.T., Ganesh, S., Kuipers, E.J., Sluiter, W.J., Karrenbeld, A., de Jager-Krikken, A. et al. (2000) Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett's esophagus. Scand J Gastroenterol 35: 1238-1244.
94. Peters, F.T., Ganesh, S., Kuipers, E.J., Sluiter, W.J., Klinkenberg-Knol, E.C., Lamers, C.B.H.W. et al. (1999) Endoscopic regression of Barrett's esophagus during omeprazole treatment: a randomised double blind study. Gut 45: 489-494.
95. Peters, F.P., Kara, M.A., Rosmolen, W.D., ten Kate, F.J.W., Bultje, A.C., Krishnadath, K.K. et al. (2005) Endoscopic resection combined with photodynamic therapy for high grade dysplasia and early cancer in Barrett's esophagus. Eur J Gastroenterol Hepatol 17: 29-30.
96. Peters, F.P., Kara, M.A., Rosmolen, W.D., ten Kate, F.J.W., Krishnadath, K.K., van Lanschot, J.J. et al. (2006) Stepwise radial endoscopic resection for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 101: 1449-1457.
97. Poelmans, J., Feenstra, L., Demedts, I., Rutgeerts, P. and Tack, J. (2004) The yield of upper gastrointestinal endoscopy in patients with suspected reflux-associated chronic ear, nose and throat symptoms'. Am J Gastroenterol 99: 1419-1426.
98. Prasad, G.A., Wang, K.K., Buttar, N.S., Wongkeesong, L.M., Krishnadath, K.K., Nichols, F.C.3rd et al. (2007) Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 132: 1226-1233.
99. Rastogi, A., Puli, S., El-Serag, H.B., Bansal, A., Wani, S. and Sharma, P. (2008) Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 67: 394-398.
100. Reid, B.J., Blount, P.L., Feng, Z. and Levine, D.S. (2000 a) Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 95: 3089-3096.
101. Reid, B.J., Haggitt, R.C., Rubin, C.E., Roth, G., Surawicz, C.M., van Belle, G. et al. (1988) Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19: 166-178.
102. Reid, B.J., Levine, D.S., Longton, G., Blount, P.L. and Rabinovitch, P.S. (2000 b) Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subjects. Am J Gastroenterol 95: 1669-1676.
103. Robert, M.E. (2003) Defining dysplasia in Barrett esophagus. J Clin Gastroenterol 36(5 Suppl): S19-S28.
104. Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E. et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129: 1825-1831.
105. Rothstein, R., Chang, K., Overholt, B.F., Bergman, J. and Shaheen, N. (2007) Focal ablation for treatment of dysplastic and non-dysplastic Barrett esophagus: safety profile and initial experience with the Halo 90 device in 508 cases. Gastrointest Endosc 65: AB147.
106. Sabik, J.F., Rice, T.W., Goldblum, J.R., Koka, A., Kirby, T.J., Medendorp, S.V. et al. (1995) Superficial esophageal adenocarcinoma. Ann Thorac Surg 60: 896-902.
107. Sampliner, R.E. (1997) Ablative therapies for the columnar-lined esophagus. Gastroenterol Clin N Am 26: 685-694.
108. Sampliner, R.E. (2003) Multipolar electrocoagulation. Gastroenterol Clin N Am 13: 449-455.
109. Sampliner, R.E. and the Practice Parameters Committee of the American College of Gastroenterology (2002) Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 97: 1888-1895.
110. Schnell, T., Sontag, S., Chejfec, G., Aranha, G., Metz, A., O'Connell, S. et al. (2001) Long-term non-surgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 120: 1607-1619.
111. Schulz, H., Miehlke, S., Antos, D., Schentke, K.U., Vieth, M., Stolte, M. et al. (2000) Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high dose omeprazole. Gastrointest Endosc 51: 659-663.
112. Scotiniotis, I.A., Kochman, M.L., Lewis, J.D., Furth, E.E., Rosato, E.F. and Ginsberg, G.G. (2001) Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 54 (6):689-96.
113. Seewald, S., Akaraviputh, T., Seitz, U., Brand, B., Groth, S., Mendoza, G. et al. (2003) Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 57: 854-859.
114. Shaheen, N.J., Crosby, M.A., Bozymski, E.M. and Sandler, R.S. (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119: 333-338.
115. Shaheen, N.J., Inadomi, J.M., Overholt, B.F. and Sharma, P. (2004) What is the best management strategy for high grade dysplasia in Barrett's esophagus? A cost effectiveness analysis. Gut 53: 1736-1744.
116. Sharma, P., McQuaid, K., Dent, J., Fennerty, M.B., Sampliner, R., Spechler, S. et al. (2004) A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago workshop. Gastroenterology 127: 310-330.
117. Sharma, P., Falk, G., Weston, A., Reker, D., Johnston, M. and Sampliner, R. (2006) Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clinical Gastroenterology and Hepatology 4 (5): 566-72.
118. Sharma, V.K., Kim, H.J., Musil, D., Crowell, M.D., Dean, P. and Fleischer, D.E. (2007 a) Circumferential ablation of Barrett esophagus with low grade dysplasia: one and two year follow up of the AIM-LGD trial. Gastrointest Endosc 65: 155.
119. Sharma, V.K., Wang, K.K., Overholt, B.F., Lightdale, C.J., Fennerty, M.B., Dean, P.J. et al. (2007 b) Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow up of 100 patients. Gastrointest Endosc 65: 185-195.
120. Shepherd, N.A. (2000) Dysplasia in Barrett's esophagus. Acta Endoscopica 30: 123-132.
121. Skacel, M., Petras, R.E., Gramlich, T.L., Sigel, J.E., Richter, J.E. and Goldblum, J.R. (2000) The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 95: 3383-3387.
122. Souza, R.F., Shewmake, K., Beer, D.G., Cryer, B. and Spechler, S.J. (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60: 5767-5772.
123. Souza, R.F., Shewmake, K., Terada, L.S. and Spechler, S.J. (2002) Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology 122: 299-307.
124. Spechler, S.J. (2001) Disputing dysplasia. Gastroenterology 120: 1864-1868.
125. Spechler, S.J. (2002) Barrett's esophagus. N Engl J Med 346: 836-842.
126. Spechler, S.J. (2003) The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. J Clin Gastroenterol 36(5 Suppl): S2-S5, S26-8.
127. Spechler, S.J. and Goyal, R.K. (1985) Barrett's Esophagus: Pathophysiology, Diagnosis and Management. Elsevier: New York.
128. Spechler, S.J., Lee, E., Ahnen, D., Goyal, R.K., Hirano, I., Ramirez, F. et al. (2001) Long-term outcome of medical and surgical treatments for gastresophageal reflux disease. Follow-up of a randomized controlled trial. JAMA 285: 2331-2338.
129. Spechler, S.J., Jain, S.K., Tendler, D.A. and Parker, R.A. (2002) Racial differences in the frequency of symptoms and complications of gastro-esophageal reflux disease. Aliment Pharmacol Ther 16: 1795-1800.
130. Tan, W.C., Fulljames, C., Stone, N., Dix, A.J., Shepherd, N., Roberts, D.J.H. et al. (1999) Photodynamic therapy using 5-aminolevulinic for esophageal adenocarcinoma associated with Barrett's metaplasia. J Photochem Photobiol B 53: 75-80.
131. Thiesen, J., Nehra, D., Citron, D., Johansson, J., Hagen, J.A., Crookes, P.F. et al. (2000) Suppression of gastric acid secretion in patients with gastresophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 4: 50-54.
132. Thomas, P., Doddoli, C., Lienne, P., Morati, N., Thirion, X., Garbe, L. et al. (1997) Changing patterns and surgical results in adenocarcinoma of the esophagus. Br J Surg 84: 119-125.
133. Toruner, M., Soykan, I., Ensari, A., Kuzu, I., Yurdaydin, C. and Ozden, A. (2004) Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol 19: 535-540.
134. Trier, J.S. (1970) Morphology of the epithelium of the distal esophagus in patients with mild esophageal strictures. Gastroenterology 58: 444-461.
135. Tsibouris, P., Hendrickse, T. and Isaacs, P. (2004) Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's esophagus who develop an esophageal adenocarcinoma. Aliment Pharmacol Ther 20: 645-655.
136. van Blankenstein, M., Bohmer, C.J.M. and Hop, W.C.J. (2004) The incidence of adenocarinoma in Barrett's esophagus in an institutionalized population. Eur J Gastroenterol Hepatol 16: 903-909.
137. van Blankenstein, M., Looman, C.W.N., Johnston, B.J. and Caygill, C.P.J. (2005) Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 100: 568-576.
138. van der Veen, A.H., Dees, J., Blankensteijn, J.D. and van Blankenstein, M. (1989) Adenocarcinoma in Barrett's esophagus: an overrated risk. Gut 30: 14-18.
139. van Sandick, J.W., van Lanschot, J.J., Kuiken, B.W., Tytgat, G.N.J., Offerhaus, G.J. and Obertop, H. (1998) Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43: 216-222.
140. Verdu, E., Viani, F., Armstrong, D., Fraser, R., Siegrist, H.H., Pignatelli, B. et al. (1994) Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 35: 455-460.
141. Wang, K.K. and Sampliner, R.B. (2008) Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. Am J Gastroenterol 103: 788.
142. Westhoff, B., Brotze, S., Weston, A., McElhinney, C., Cherian, R., Mayo, M. et al. (2005) The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61: 226-231.
143. Weston, A.P., Banerjee, S.K., Sharma, P., Tran, T.M., Richards, R. and Cherian, R. (2001) p 53 overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 96: 1355-1362.
144. Weston, A.P., Sharma, P., Topalovski, M., Richards, R., Cherian, R. and Dixon, A. (2000) Long-term follow up of Barrett's high-grade dysplasia. Am J Gastroenterol 95: 1888-1893.
145. Wilson, K.T., Fu, S., Ramanujam, K.S. and Meltzer, S.K. (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58: 2929-2934.
146. Wipff, J., Allanore, Y., Soussi, F., Terris, B., Abitbol, V., Raymond, J. et al. (2005) Prevalence of Barrett's esophagus systematic sclerosis. Arthritis Rheum 52: 2882-2888.
147. Yang, P.C. and Davis, S. (1988) Incidence of cancer of the esophagus in the US by histologic type. Cancer 61: 612-617.
148. Ye, W., Chow, W., Lagergren, J., Lin, O. and Nyren, O. (2001) Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastresophageal reflux diseases and after reflux surgery. Gastroenterology 121: 1286-1293.